SUPPLEMENTAL MATERIAL

Table S1. Definitions of symptomatic intracerebral hemorrhage.

sICH definition	NIHSS	Imaging	
PH	None	Only PH	
NINDS	Any clinical worsening	Any ICH	
ECASSII	≥4 NIHSS	Any ICH	
mSITS-MOST	≥4 NIHSS	Only PH	

sICH: symptomatic intracranial hemorrhage; NIHSS: National Institutes of Health Stroke Scale; PH: parenchymal hemorrhage; NINDS: National Institute of Neurological Disorders and Stroke; ECASSII: European-Australian Cooperative Acute Stroke Study 2; mSITS-MOST: modified Safe Implementation of Thrombolysis in Stroke Monitoring; ICH: intracranial hemorrhage.

Scopus		
Step	Search query	Results
#1	(TITLE(stroke*) AND TITLE(Ischemic or acute or cerebral OR	
	infarct*)) OR TITLE(Large w/3 stroke*) or (TITLE(cerebrovascular)	1644
	AND TITLE(injury or failure or arrest or accident OR infarct*)) OR	
	TITLE("ischemic cerebral") OR (TITLE(Cerebral) AND	
	TITLE(Apoplexia or "vascular accident" or insult))	
#2	((TITLE(noac* OR "thrombin inhibitors") OR TITLE(new W/3	
	anticoagulant*)) OR (TITLE (plasminogen W/1 activator) OR	
	TITLE (alteplase OR tenecteplase OR "TNK tPA" OR tnkase)))	
	OR ((TITLE("Factor Xa" W/2 inhibitor) OR TITLE(direct W/2	
	anticoagulant*)) OR (TITLE(intravenous W/3 thrombolysis)) OR	
	(TITLE (direct W/2 anticoagulant*)) OR (TITLE (doac* OR	
	aban AND rivaroxaban OR apixaban OR edoxaban OR betrixaban	
	OR dabigatran)))	
Filters:	(LIMIT-TO (DOCTYPE, "ar"))	

Pubm	ed/Medline	
Step	Search query	Results
#1	"Stroke"[Mh] or (stroke[ti] or "cerebrovascular"[ti] or "ischemic	1620
	cerebral"[ti])	
#2	("Tissue Plasminogen Activator"[Mh] or "Factor Xa Inhibitors"[Mh] or	
	(noac* or 'thrombin inhibitors' OR rivaroxaban OR apixaban OR	
	edoxaban OR betrixaban OR dabigatran or alteplase OR tenecteplase OR	
	"TNK tPA" OR tnkase)) OR (((plasminogen[ti]) AND (activator[ti])) OR	
	((direct[ti]) and (anticoagulant*[ti])))	
#3	((thrombol*[ti] OR treat*[ti] OR therap*[ti]) and (intravenous[ti]))	
#4	#1 AND #2	
#5	#4 AND #3	
Emba	se	
Step	Search query	Results
#1	(((ischemic OR acute OR cerebral) NEAR/3 stroke*):ti) OR 'ischemic	678
	cerebral':ti OR (((apoplexia OR 'vascular accident' OR insult) NEAR/3	
	cerebr*):ti)	
#2	noac*:ti OR 'thrombin inhibitors':ti OR rivaroxaban:ti OR apixaban:ti OR	
	edoxaban:ti OR betrixaban:ti OR dabigatran:ti OR alteplase:ti OR	
	tenecteplase:ti OR "TNK tPA":ti OR tnkase:ti ((direct NEAR/2	
	anticoagulant*):ti) OR (('factor xa' NEAR/2 inhibitor):ti) OR	
	((plasminogen NEAR/2 activator):ti)	
#3	((thrombol* OR treat* OR therap*) NEAR/4 intravenous) OR	
	((thromboly* NEAR/3 therap*):ti,ab)	1

#4	#1 AND #2	
#5	#4 AND #3	

Web o	f Science	
Step	Search query	Results
#1	TI=(stroke*) or (TI=(cerebrovascular) and TI=(injury or failure or arrest	
	or accident OR infarct*)) OR ti=("ischemic cerebral")	
#2	TI=(Noac* or "thrombin inhibitors") or ti=(New near/3 anticoagulant*) or	
	TI=(plasminogen NEAR/2 activator) OR TI=(alteplase OR tenecteplase	
	OR "TNK tPA" OR tnkase) OR TI=("Factor Xa" NEAR/2 inhibitor) OR	
	TI=(direct NEAR/2 anticoagulant*) OR TI=(doac* OR *aban* AND	
	rivaroxaban OR apixaban OR edoxaban OR betrixaban OR dabigatran)	
	OR TI=(antagonist near/3 anticoagulant*)	
#3	TI=(Intravenous NEAR/3 Thrombolysis) OR AB=(Intravenous NEAR/3	
	Thrombolysis) OR TI=(Treat* near/3 intravenous) or AB=(Treat* near/3	
	intravenous) OR TI=(thromboly* near/3 therap*) or AB=(thromboly*	
	near/3 therap*)	
#4	#1 AND #2	
#5	#4 AND #3	
Scielo		
#1	TI=(stroke*) or (TI=(cerebrovascular) and TI=(injury or failure or arrest	11
	or accident OR infarct*)) OR ti=("ischemic cerebral")	
#2	TI=(Noac* or "thrombin inhibitors") or ti=(New near/3 anticoagulant*) or	
	TI=(plasminogen NEAR/2 activator) OR TI=(alteplase OR tenecteplase	
	OR "TNK tPA" OR tnkase) OR TI=("Factor Xa" NEAR/2 inhibitor) OR	
	TI=(direct NEAR/2 anticoagulant*) OR TI=(doac* OR *aban* AND	
	rivaroxaban OR apixaban OR edoxaban OR betrixaban OR dabigatran)	
	OR TI=(antagonist near/3 anticoagulant*)	
#3	#1 AND #2	

CEN	CENTRAL (Cochrane Library Central Register of Controlled Trials)			
Step	Search	n query	Results	
#A	#1	(stroke):ti	331	
	#2	MeSH descriptor: [Stroke] explode all trees		
	#3	((noac* or 'thrombin inhibitors' OR rivaroxaban OR apixaban OR		
	edoxaban OR betrixaban OR dabigatran or alteplase OR tenecteplase OR			
	"TNK	tPA" OR tnkase)):ti		
	#4	((Oral and anticoagulants)):ti		
	#5	((thrombol* OR treat* OR therap* or recombinant)):ti		
	#6	#1 or #2		
	#7	#3 or #4		
	#8	#6 and #7		

	#9	#8 and #5	
*Resul	ts unt	il March 2023	

Outcomes	№ of participants (studies)	Certainty of the evidence (GRADE)	Pooled Effect Size (95% CI)
sICH (comparison)	246933 (8 observational studies)	⊕⊕⊕⊖ Moderate ^a	OR 0.95 (0.67 – 1.36)
sICH (proportion)	3610 (14 observational studies)	⊕⊕⊕⊖ Moderate ^a	3% (3% - 4%)
Any ICH (comparison)	33816 (3 observational studies)	⊕⊕⊕⊖ Moderate ^a	OR 1.23 (0.61 – 2.48)
Any ICH (proportion)	1062 (11 observational studies)	⊕⊕⊕⊖ Moderate ^a	12% (7% – 19%)
Systemic Bleeding (comparison)	205218 (3 observational studies)	⊕⊕⊕⊖ Moderate ^a	OR 1.27 (0.79 – 2.02)
Systemic Bleeding (proportion)	2602 (7 observational studies)	⊕⊕⊕⊖ Moderate ^a	1% (0% – 1%)
mRS at 90 days (comparison)	30687 (3 observational studies)	⊕⊕⊕⊖ Moderate ^{a,b}	OR 1.22 (0.4 – 3.69)
mRS at 90 days (proportion)	776 (7 observational studies)		57% (43% – 70%)

 Table S3. Summary of certainty of the evidence.

Explanations

a. Measured with the ROBINS-I tool.

b. Wide confidence interval.

c. Tau squared.

Table S4. Table of studies excluded.

Author	Title	Reason for exclusion
Emberson et al	Details of a Prospective Protocol for a Collaborative Meta-Analysis of Individual Participant Data from all Randomized Trials of Intravenous rt-PA vs. Control: Statistical Analysis Plan for the Stroke Thrombolysis Trialists' Collaborative Meta-Analysis 2013	Irrelevant to the topic
AAorn S et al	Acute Ischemic Stroke in Term Pregnancy Treated with Recombinant Tissue Plasminogen Activator 2020	Irrelevant to the topic
AbdelRazek et al	Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study 2018	Irrelevant to the topic
Abdullah et al:	Advance hospital notification by EMS in acute stroke is associated with shorter door-to- computed tomography time and increased likelihood of administration of tissue- plasminogen activator 2008	Irrelevant to the topic
Abraham et al	The need for a population-based, dose optimization study for recombinant tissue plasminogen activator in acute ischemic stroke: A study from a tertiary care teaching hospital from South India 2017	Irrelevant to the topic
Agarwal et al	Redefined Measure of Early Neurological Improvement Shows Treatment Benefit of Intravenous Tissue Plasminogen Activator Treatment in NINDS Rt-PA Acute Stroke Trial at 24 Hours 2020	Irrelevant to the topic
Alamowitch et al	European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke 2023	Irrelevant to the topic
Alberts et al	Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin 2020	Irrelevant to the topic
Balogun et al	A Stroke Registry Data on the Use of Intravenous Recombinant Tissue Plasminogen Activator in Stroke of Unknown Time of Onset 2016	Irrelevant to the topic
Broocks et al	Benefit and risk of intravenous alteplase in patients with acute large vessel occlusion stroke and low ASPECTS 2022	Irrelevant to the topic
Calleja et al	Collateral circulation on perfusion-computed tomography-source images predicts the response to stroke intravenous thrombolysis 2013	Irrelevant to the topic
Chen et al:	Neutrophil Counts to High-Density Lipoprotein Cholesterol Ratio: a Potential Predictor of Prognosis in Acute Ischemic Stroke Patients After Intravenous Thrombolysis 2020	Irrelevant to the topic
Deitelzweig et al	An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants 2016	Irrelevant to the topic

The relationship between serum bilirubin levels and early neurological improvement in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator 2022	Irrelevant to the topic
Intravenous thrombolysis for treatment of pediatric acute ischemic stroke: Analysis of 20 years of population-level data in the United States 2022	Irrelevant to the topic
Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study 2016	Irrelevant to the topic
The role of leukoaraiosis on outcomes and recombinant tissue-plasminogen activator- related symptomatic intracerebral hemorrhages in acute stroke 2020	Irrelevant to the topic
Dabigatran initiation in patients with non-valvular AF and first acute ischaemic stroke: a retrospective observational study from the SITS registry 2020	Irrelevant to the topic
Intravenous Fibrinolysis in ischemic stroke of large vessel after reversing effect with idraucizumab 2017	Abstract
Systemic thrombolysis and endovascular thrombectomy in severe ischmeic stroke after dabigatran reversal with idarucizumab 2018	Abstract
Recent use of Non-vitamin K antagonist oral anticoagulants and intracranial Hemorrhage Among patients with acute ischemic stroke treated with Alteplase 2022	Abstract
Successful intravenous thrombolysis in acute ischaemic stroke in a patient on rivaroxaban treatment 2013	Abstract
Acute ischemic stroke in patient on treatment with non-vitamin K oral anticoagulants- safety and efficacy of NOAC plasma-level-guided therapy 2018	Abstract
Intravenous thrombolysis for ischemic stroke in patients receiving dabigatran 2014	Abstract
Emergency measurement of plasma levels for rivaroxaban in patients with acute stroke is feasible in median of 34 minutes	Abstract
Successful intravenous alteplase use in four patients with acute ischemic stroke after dabigatran reversal with idarucizumab 2018	Abstract
Revascularization therapy in acute stroke patients treated with NOAC should be safe 2016	Abstract
	patients with acute ischemic stroke treated with intravenous tissue plasminogen activator 2022 Intravenous thrombolysis for treatment of pediatric acute ischemic stroke: Analysis of 20 years of population-level data in the United States 2022 Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study 2016 The role of leukoaraiosis on outcomes and recombinant tissue-plasminogen activator- related symptomatic intracerebral hemorrhages in acute stroke 2020 Dabigatran initiation in patients with non-valvular AF and first acute ischaemic stroke: a retrospective observational study from the SITS registry 2020 Intravenous Fibrinolysis in ischemic stroke of large vessel after reversing effect with idraucizumab 2017 Systemic thrombolysis and endovascular thrombectomy in severe ischmeic stroke after dabigatran reversal with idarucizumab 2018 Recent use of Non-vitamin K antagonist oral anticoagulants and intracranial Hemorrhage Among patients with acute ischemic stroke treated with Alteplase 2022 Successful intravenous thrombolysis in acute ischaemic stroke in a patient on rivaroxaban treatment 2013 Acute ischemic stroke in patient on treatment with non-vitamin K oral anticoagulants- safety and efficacy of NOAC plasma-level-guided therapy 2018 Intravenous thrombolysis for ischemic stroke in patients with acute stroke is feasible in median of 34 minutes Successful intravenous alteplase use in four patients with acute ischemic stroke after dabigatran reversal with idarucizumab 2018 Revascularization therapy in acute stroke patients treated with NOAC should be safe

Bartoli et al	Early Carotid Endarterectomy after Intravenous Thrombolysis for Acute Ischaemic Stroke 2009	Case Report
Berliner et al	Successful Outcome in an Adolescent with Artery of Percheron Occlusion who was Treated with Tissue Plasminogen Activator 2022	Case Report
Bornkamm et al	Safe intravenous thrombolysis in acute stroke despite treatment with rivaroxaban 2014	Case Report
Bouchal et al	Repeated intravenous thrombolysis in early recurrent stroke secondary to carotid web: Case report 2021	Case Report
Bourdial et al	Intravenous thrombolysis in pediatric arterial ischemic stroke: A Case Report and a review of the literature 2008	Case Report
Camara- Lemarroy et al	Successful intravenous thrombolysis in a patient with antiphospholipid syndrome, acute ischemic stroke and severe thrombocytopenia 2016	Case Report
Cao et al	Successful intravenous thrombolysis for acute ischemic stroke caused by aortic dissection with severe hypofibrinogenemia: a case report and Literature review 2022	Case Report
Chao et al	Thrombolysis in an acute ischemic stroke patient with rivaroxaban anticoagulation A case report 2019	Case Report
Folyovich et al	Dilemma of indication for thrombolysis in a patient with acute ischemic stroke treated with a novel oral anticoagulant	Case Report
Fontaine et al	Alteplase for Acute Ischemic Stroke after Heparin Reversal with Protamine: A case report and Review 2017	Case Report
Haghighi et al	Fibrinolytic treatment for acute ischaemic stroke in a patient on dabigatran etexilate	Case Report
Giannandrea et al	Intravenous thrombolysis in stroke after dabigatran reversal with idarucizumab	Case Report

2017 REVERSAL OF THE ANTICOAGULATION EFFECTS OF DABIGATRAN ETEXILATE BY IDARUCIZUMAB IN THREE PATIENTS NEEDING URGENT SURGICAL INTERVENTION AND ONE CASE OF INTRAVENOUS THROMBOLYSIS IN ISCHAEMIC STROKE	Case Report
Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator 2017	Case Report
Safety of Intravenous Thrombolysis and Mechanical Thrombectomy in Bilateral Posterior Cerebral Artery Territory Infarction 2022	Case Report
Intravenous thrombolysis for acute ischemic stroke due to cardiac myxoma 2020:	Case Report
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) 2017	Wrong population
Endovascular Treatment for Acute Ischemic Stroke in Patients on Oral Anticoagulants 2020: wrong population	Wrong population
Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke 2014	Wrong population
Coagulation Testing in Acute Ischemic Stroke Patients Taking Non–Vitamin K Antagonist Oral Anticoagulants 2016	Wrong population
Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome 2015	
Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute Wrether the stroke 2016	
Trends in direct oral anticoagulant use in patients presenting with acute stroke 2022	Wrong population
	SURGICAL INTERVENTION AND ONE CASE OF INTRAVENOUS THROMBOLYSIS IN ISCHAEMIC STROKE Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator 2017 Safety of Intravenous Thrombolysis and Mechanical Thrombectomy in Bilateral Posterior Cerebral Artery Territory Infarction 2022 Intravenous thrombolysis for acute ischemic stroke due to cardiac myxoma 2020: Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) 2017 Endovascular Treatment for Acute Ischemic Stroke in Patients on Oral Anticoagulants 2020: wrong population Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke 2014 Coagulation Testing in Acute Ischemic Stroke Patients Taking Non–Vitamin K Antagonist Oral Anticoagulants 2016 Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome 2015 Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke 2016

Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non–Vitamin K Antagonist Oral Anticoagulants Preceding Stroke 2018: Systematic review	Review article
Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature 2021: review	Review article
Meta-analysis of the efficacy and safety of intravenous alteplase in the treatment of acute minor ischemic stroke 2022: meta-analysis	Review article
Confidence in the Use of Direct Oral Anticoagulants in the Acute Phase of Nonvalvular Atrial Fibrillation–Related Ischemic Stroke Over the Years: A Real-World Single-Center Study 2018: Review	Review article
Management of patients with stroke treated with direct oral anticoagulants 2018: Review	Review article
Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis	Review article
Safety of Recanalization Therapy in Patients with Acute Ischemic Stroke Under Anticoagulation: A Systematic Review and Meta-Analysis	Review article
Recent Use of Non–Vitamin K Antagonist Oral Anticoagulants and Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase 2022	Experts' statements and guidelines
017 Intravenous thrombolysis in a stroke patient taking dabigatran	
2017 Intravenous Thrombolysis in Acute Ischemic Stroke Patients Pretreated With Non- Vitamin K Antagonist Oral Anticoagulants	Experts' statements and guidelines
2022 Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants and Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With AlteplaseExample Anticoagulants article Anticoagulants	
Emergency management of acute ischemic stroke: the evolving roles of intravenous and endovascular therapies 2013	Experts' statements and guidelines
	 Stroke Taking Non–Vitamin K Antagonist Oral Anticoagulants Preceding Stroke 2018: Systematic review Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature 2021: review Meta-analysis of the efficacy and safety of intravenous alteplase in the treatment of acute minor ischemic stroke 2022: meta-analysis Confidence in the Use of Direct Oral Anticoagulants in the Acute Phase of Nonvalvular Atrial Fibrillation–Related Ischemic Stroke Over the Years: A Real-World Single-Center Study 2018: Review Management of patients with stroke treated with direct oral anticoagulants 2018: Review Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis Safety of Recanalization Therapy in Patients with Acute Ischemic Stroke Under Anticoagulation: A Systematic Review and Meta-Analysis Recent Use of Non–Vitamin K Antagonist Oral Anticoagulants and Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase 2022 Intravenous thrombolysis in a stroke patient taking dabigatran 2017 Intravenous Thrombolysis in Acute Ischemic Stroke Patients Pretreated With Non– Vitamin K Antagonist Oral Anticoagulants 2022 Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants and Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Patients Pretreated With Non– Vitamin K Antagonist Oral Anticoagulants 2022 Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants and Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase Emergency management of acute ischemic stroke: the evolving roles of intravenous and

Xian et al	Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients with Atrial Fibrillation and Ischemic Stroke: Findings from the Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study 2019	Overlapping population
Oblak et al	Intravenous Thrombolysis After Idarucizumab Application in Acute Stroke Patients—A Potentially Increased Sensitivity of Thrombi to Lysis? 2019	Overlapping population
Frol et al	Revascularization outcomes following acute ischemic stroke in patients taking direct oral anticoagulants: a single hospital cohort study. Journal of Thrombosis and Thrombolysis	Overlapping population

Table S5. Additional characteristics of studies.

Study	Study design	Country	Study period	sICH definition
Meinel et al. (2023) ³²	Retrospective MC	Australia, Canada, China, England, Germany, Hong Kong, Israel, Italy, Japan, New Zealand, Norway, South Korea, Switzerland	2008 - 2021	Any ICH as reported by the site investigators within 36 hours after IVT with worsening NIHSS score of at least 4 points
Kam et al. (2022) ³³	Retrospective MC	United States	April 1, 2015 - March 31, 2020	Any ICH within 36 hours by either CT or MRI, with noting a clinical deterioration from that hemorrhage
Kikule et al. (2022) ³⁹	Retrospective SC	Latvia	2018 - 2022	NR
Okada et al. (2022) ³⁴	Prospective SC	Japan	March 2011 - January 2021	ECASS-III
Frol et al. (2021) ³⁵	Prospective SC	Slovenia	September 2016 – March 2020	ECASS-II
Beharry et al. (2020) ³⁷	Retrospective MC	New Zealand and Australia	Unknown	PH2
Kermer et al. (2020) ⁴⁰	Retrospective MC	Germany	January 2016 – August 2018	Any ICH with clinical deterioration (indicated by increase in NIHSS) with follow-up CT scan
Fang et al. (2019) ³⁸	Retrospective MC	Taiwan	May 2016 – May 2018	ICH that causes at least a 4- point increase of the NIHSS score or mortality
Šaňák et al. (2018) ⁴¹	Retrospective MC	Czech Republic	Unknown	SITS-MOST
Xian et al. (2017) ³⁶	Retrospective MC	United States	October 2012 – March 2015	Like Kam et al 2022
Seiffge et al. (2017) ^{22,23}	Prospective SC	Switzerland	September 2012 – November 2016	ECASS-II or NINDS
Tse et al. (2017) ⁴²	Retrospective MC	New Zealand	July 1, 2016 – December 31, 2016	PH2 and ≥4point increase in NIHSS score

Suzuki et al. (2017) ⁴³	Retrospective MC	Japan	March 2011 – February 2015	ECASS-II
Shahjouei et al. (2015) ⁴⁴	Retrospective MC	United States, Greece	October 2010 – October 2014	NINDS and Stroke tPA trial definition

MC: Multicenter; SC: Single center; sICH: symptomatic intracranial hemorrhage; NIHSS: National Institutes of Health Stroke Scale; PH: parenchymal hemorrhage; NINDS: National Institute of Neurological Disorders and Stroke; ECASS II or III: European-Australian Cooperative Acute Stroke Study 2 or 3; mSITS-MOST: modified Safe Implementation of Thrombolysis in Stroke Monitoring. CT: computed tomography; MRI: magnetic resonance imaging; ICH: intracranial hemorrhage; NR: not reported.

Table S6. Characteristics of Direct oral anticoagulants.

Study	Dabigatran (n)	Rivaroxaban (n)	Apixaban (n)	Edoxaban (n)	Not specified (n)	DOAC within 48 hours of onset (n)	DOAC within 24 hours of onset (n)	Idarucizumab (n)
Meinel et al. 2023 ³²	342	258	163	68	1	832	400	252
Kam et al. 2022 ³³	-	-	-	-	2207	25	8	0
Kikule et al. 2022 ³⁹	9	0	0	0	0	-	-	9
Okada et al. 2022 ³⁴	6	8	16	10	0	40	40	2
Frol et al. 2021 ³⁵	22	0	0	0	0	-	-	22
Beharry et al. 2020 37	13	0	0	0	0	7	7	13
Kermer et al. 2020 ⁴⁰	80	0	0	0	0	-	-	80
Fang et al. 2019 ³⁸	10	0	0	0	0	9	9	10
Šaňák et al. 2018 ⁴¹	13	0	0	0	0	13	13	13
Xian et al. 2017 ³⁶	87	129	35	0	0	-	-	0
Seiffge et al. 2017 ²²⁻²³	0	18	0	0	33	51	18	0
Tse et al. 2017 ⁴²	6	0	0	0	0	-	-	6
Suzuki et al. 2017 ⁴³	-	-	-	-	71	56	-	0
Shahjouei et al. 2015 ⁴⁴	5	0	0	0	0	5	5	0

Table S7. Assessment of publication bias using the Egger's test for studies including each outcome.

Metanalysis of proportions			
	p-value		
sICH	0.40		
Any ICH	0.11		
Systemic Bleeding	0.10		
Mortality at 90 days	0.19		
mRS 0-2 at 90 days	0.15		
Compara	tive analysis		
p-value			
sICH	0.54		
Any ICH	0.70		
Systemic Bleeding	0.84		
Mortality at 90 days	0.84		
mRS 0-2 at 90 days	0.23		

sICH: symptomatic intracranial hemorrhage

ICH: intracranial hemorrhage mRS: modified Rankin Scale

Table S8. Sensitivity analyses, MA of proportions.

Outcome	No of studies	No of participants	Pooled rate (95% CI)		
DOAC use < 48 hour	DOAC use < 48 hours of stroke onset				
sICH	9	1038	0.03 (0.02 to 0.04)		
Any ICH	6	869	0.17 (0.15 to 0.20)		
Systemic Bleeding	4	83	0.01 (0.00 to 0.08)		
mRS 0-2 at 90 days	4	735	0.46 (0.42 to 0.49)		
DOACs use < 48 hou	rs of stroke onset +	no idarucizumab			
sICH	5	717	0.03 (0.02 to 0.05)		
Idarucizumab was g	Idarucizumab was given < IVT				
sICH	8	405	0.03 (0.01 to 0.07)		
Idarucizumab was n	Idarucizumab was not given < IVT				
sICH	6	3150	0.04 (0.03 to 0.04)		

No: number; MA: meta-analysis; DOAC: direct oral anticoagulant; mRS: modified Rankin Scale; sICH: symptomatic intracranial hemorrhage; ICH: intracranial hemorrhage; <: prior to; IVT: intravenous thrombolysis; CI: confidence interval

Table S9. Sensitivity analyses, pairwise comparison.

Outcome	No of studies	DOAC: events/total	No DOAC: events/total	Odds ratio (95% CI)		
DOAC use in	n last 48 hour	rs < stroke onset				
sICH	6	27/1009	7024/202151	0.79 (0.45 to 1.37)		
DOAC use in	DOAC use in last 48 hours < stroke onset + no idarucizumab was given < IVT					
sICH	5	23/717	7006/201398	0.83 (0.55 to 1.25)		

No: number; DOAC: direct oral anticoagulant; <: prior to

Outcomes	№ of participants (studies)	Certainty of the evidence (GRADE)	Pooled Effect Size (95% CI)	
sICH (comparison)	246933 (8 observational studies)	⊕⊕⊕⊖ Moderate ^a	OR 0.95 (0.67 – 1.36)	
sICH (proportion)	3610 (14 observational studies)	⊕⊕⊕⊖ Moderate ^a	3% (3% - 4%)	
Any ICH (comparison)	33816 (3 observational studies)	$\oplus \oplus \oplus \bigcirc$ Moderate ^a	OR 1.23 (0.61 – 2.48)	
Any ICH (proportion)	1062 (11 observational studies)	⊕⊕⊕⊖ Moderate ^a	12% (7% – 19%)	
Systemic Bleeding (comparison)	205218 (3 observational studies)	⊕⊕⊕⊖ Moderate ^a	OR 1.27 (0.79 – 2.02)	
Systemic Bleeding (proportion)	2602 (7 observational studies)	⊕⊕⊕⊖ Moderate ^a	1% (0% - 1%)	
mRS at 90 days (comparison)	30687 (3 observational studies)	⊕⊕⊕⊖ Moderate ^{a,b}	OR 1.22 (0.4 – 3.69)	
mRS at 90 days (proportion)	776 (7 observational studies)	⊕○○○ Very low ^{a,b,c}	57% (43% - 70%)	

Explanations

a. Measured with the ROBINS-I tool.

b. Wide confidence interval.


c. Tau squared.


Table S11. Tau-squared for evaluation of heterogeneity.


Outcomes	Tau2 (95% CI)
Meta-analyses of binary outcomes	· · · ·
Symptomatic ICH	0.02(0.00 - 1.62)
Any ICH	0.42 (0.00 - 29.36)
Systemic Bleeding	0 (0.00 – 25.58)
Mortality at 90 days	0 (0.00 – 5.66)
mRS 0-2 at 90 days	0.93 (0.08 - 47.13)
sICH (Only 48 hours)	0.05 (0.00 - 5.79)
sICH (Only 48 hours, no idarucizumab)	0.08 (0.25 – 3.19)
Meta-analyses of proportions*	
Symptomatic ICH	0.00
sICH (Only 48 hours)	0.00
Any ICH	0.42
Any ICH (Only 48 hours)	0.00
Systemic Bleeding	0.00
Systemic Bleeding (Only 48 hours)	0.00
Mortality at 90 days	0.00
Mortality at 90 days (Only 48 hours)	0.00
mRS 0-2 at 90 days	0.34
mRS 0-2 at 90 days (Only 48 hours)	0.00
sICH (Only 48 hours, no idarucizumab)	0.00

mRS: modified Rankin Scale; sICH: symptomatic intracranial hemorrhage; ICH: intracranial hemorrhage; CI: confidence interval.


*No method available to calculate the tau-squared CI.








Bias due to confounding Bias due to selection of participants Bias in classification of interventions Bias due to deviations from intended interventions Bias due to missing data Bias in measurement of outcomes Bias in selection of the reported result **Overall risk of bias**





sICH: symptomatic intracranial hemorrhage




Figure S4. Forest plot for IVT in patients were taking DOAC for functional independence at 90 days.

A: referring to the meta-analysis of proportions. B: referring to the comparative analysis.

CI: confidence interval; DOAC: direct oral anticoagulant

sICH: symptomatic intracranial hemorrhage




Figure S5. Forest plot for IVT in patients were taking DOAC for excellent outcome (mRS 0-1) at 90 days.

CI: confidence interval




Figure S6. Forest plot for proportion of mortality at 90 days in patients who received IVT and were taking DOAC.

CI: confidence interval




Figure S7. Sensitivity analysis for proportion of mortality at 90 days in patients who received IVT and were taking DOAC.




Figure S8. Baujat plot for proportion of mortality at 90 days in patients who received IVT and were taking DOAC.




Figure S9. Forest plot for comparison in mortality rate for IVT between patients were taking DOAC vs who were not taking DOAC.

CI: confidence interval




Figure S10. Sensitivity analysis for comparison of mortality at 90 days in patients who received IVT and were taking DOAC as compared to none.




Figure S11. Baujat plot for comparison of mortality at 90 days in patients who received IVT and were taking DOAC as compared to none.

Subgroup	Events	Total	GLMM, Random, 95% CI	GLMM, Random, 95% CI
NIHSS = >10				
Meinel et al., 2023	21	832	0.03 [0.02; 0.04]	-
Okada et., 2022	1	40	0.02 [0.00; 0.13]	
Frol et al., 2021	1	22	0.05 [0.00; 0.23]	-
Fang et al., 2019	1	10	0.10 [0.00; 0.45]	
Xian et al., 2017	12	251	0.05 [0.02; 0.08]	H -
Seiffge et al., 2017	0	18	0.00 [0.00; 0.19]	
Tse et al., 2017	1	6	0.17 [0.00; 0.64]	
Suzuki et al., 2017	0	71	0.00 [0.00; 0.05]	<u>1</u>
Total (95% CI)		1250	0.03 [0.02; 0.04]	•
Heterogeneity: $Tau^2 = 0.0$	0280; Chi ²	² = 7.26	, df = 7 (P = 0.40); I ² = 4%	
NIHSS = =10				
Kam et al., 2022	81	2207	0.04 [0.03; 0.05]	-
Kikule et al., 2022	1	9	0.11 [0.00; 0.48]	
Beharry et al., 2020	0	13	0.00 [0.00; 0.25]	
Kermer et al., 2020	0	80	0.00 [0.00; 0.05]	— —
Šanák et al., 2018	1	13	0.08 [0.00; 0.36]	
Shahjouei et al., 2015	0	5	0.00 [0.00; 0.52]	
Total (95% CI)		2327	0.04 [0.03; 0.04]	•
Heterogeneity: $Tau^2 = 0$;	Chi ² = 1.7	′8, df =	5 (P = 0.88); I ² = 0%	
Total (95% CI)		3577	0.03 [0.02; 0.04]	<u> </u>
Heterogeneity: $Tau^2 = 0.0$	0064; Chi ²	² = 9.26	, df = 13 (P = 0.75); I ² = 0%	
Test for subgroup different	nces: Chi ²	= 0.55	, df = 1 (P = 0.46)	0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
				Pooled Proportion



Α

Subgroup	Events	Total	GLMM, Random, 95% CI	GLMM, Random, 95% Cl		
Idarucizumab = Yes			•••••••••••••••••••••••••••••••••••••••	C , C , C		
Meinel et al., 2023	3	252	0.01 [0.00; 0.03]			
Kikule et al., 2022	1	9	0.11 [0.00; 0.48]			
Frol et al., 2021	1	22	• • •	- B		
Beharry et al., 2020	0	13				
Kermer et al., 2020	0	80	• • •			
Fang et al., 2019	1	10	0.10 [0.00; 0.45]			
Šanák et al., 2018	1	13	0.08 [0.00; 0.36]			
Tse et al., 2017	1	6	0.17 [0.00; 0.64]			
Total (95% CI)		405	0.03 [0.01; 0.07]	◆		
Heterogeneity: Tau ² = 0.6746; Chi ² = 9, df = 7 (P = 0.25); $I^2 = 22\%$						
Idarucizumab = No						
Meinel et al., 2023	18	580	0.03 [0.02; 0.05]	-		
Kam et al., 2022	81	2207	0.04 [0.03; 0.05]	+		
Xian et al., 2017	12	251	0.05 [0.02; 0.08]	- -		
Seiffge et al., 2015&2017*	3	51	0.06 [0.01; 0.16]			
Suzuki et al., 2017*	0	56	0.00 [0.00; 0.06]			
Shahjouei et al., 2015	0	5				
Total (95% CI)		3150	0.04 [0.03; 0.04]	•		
Heterogeneity: $Tau^2 = 0$; $Chi^2 = 2.07$, $df = 5$ (P = 0.84); $I^2 = 0\%$						
Total (95% CI)		3555	0.03 [0.03; 0.04]	•		
Heterogeneity: Tau ² = 0; Chi ²	= 11.16, c	$(P = 0.60); I^2 = 0\%$				
Test for subgroup differences:	Chi ² = 0.3	1 (P = 0.54)	0 0.1 0.2 0.3 0.4 0.5 0.6 0.7			
÷ .						

Pooled Proportion

0.7

Figure S12. Forest plot for subgroup analysis for sICH.

A: NIHSS >10 vs. \leq 10. B: received idarucizumab vs. no idarucizumab. *: direct communication with the authors. sICH: symptomatic intracranial hemorrhage; NIHSS: National Institutes of Health Stroke Scale; CI: confidence interval.